Long term treatment and disease severity change brain responses to levodopa in Parkinson’s disease

T Hershey, K J Black, J L Carl, L McGee-Minnich, A Z Snyder, J S Perlmutter

J Neurol Neurosurg Psychiatry 2003;74:844–851

Objective: Degeneration of nigrostriatal neurons and subsequent striatal dopamine deficiency produce many of the symptoms of Parkinson disease (PD). Initially, restoration of striatal dopamine with oral levodopa provides substantial benefit, but with long term treatment and disease progression, levodopa can elicit additional clinical symptoms, reflecting altered effects of levodopa in the brain. The authors examined whether long term treatment affects the brain’s response to levodopa in the absence of these altered clinical responses to levodopa.

Methods: Positron emission tomography (PET) measurements were used to measure brain blood flow before and after an acute dose of levodopa in three groups: PD patients treated long term with levodopa without levodopa induced dyskinesias, levodopa naive PD patients, and controls.

Results: It was found that the PD group treated long term responded to acute levodopa differently from controls in left sensorimotor and left ventrolateral prefrontal cortex. In both regions, the treated PD group had decreased blood flow whereas the control group had increased blood flow in response to levodopa. Levodopa naive PD patients had little or no response to levodopa in these regions. Within the treated PD group, severity of parkinsonism correlated with the degree of abnormality of the sensorimotor cortex response, but not with the prefrontal response.

Conclusions: It is concluded that long term levodopa treatment and disease severity affect the physiology of dopaminergic pathways, producing altered responses to levodopa in brain regions associated with motor function.

METHODS

Subjects

Patients with clinically diagnosed idiopathic PD (n=28) were recruited from the Movement Disorders Center at Washington University School of Medicine. Patients were excluded from the study for any evidence of secondary parkinsonism (for example, drug induced or atypical presentation), dementia (Mini-Mental Status Exam (MMSE) score <26), depression (Hamilton Scale score >10), history of levodopa induced dyskinesias or psychosis, history of other neurological disorders, psychiatric disorders, substance misuse, neuroleptic use, or suspicion of pregnancy. Patients either were chronically treated with levodopa (treated PD; n=12; average daily dose of levodopa =452 mg, SD=311 mg) or had no history of levodopa or other dopamine agonist treatment (levodopa naive PD; n=16). Three of the 12 treated PD patients were also taking an additional dopamine agonist (one subject taking pramipexole, bromocriptine, and pergolide). Normal controls also were scanned (controls; n=16). The three groups did not differ significantly in age (table 2, F(2,41)=2.41, p=0.10), however, the control group was on average younger than the two PD groups. All subjects were right handed. Eight of the 12 treated PD patients and 8 of the 16 levodopa naive PD patients had greater symptoms on

Abbreviations: PD, Parkinson’s disease; PET, positron emission tomography
the right side of the body. Four of the 12 treated PD patients noted slight diminution of motor benefit before a dose of levodopa, but none were taking levodopa more than four times per day. The two PD groups differed significantly in symptom duration and baseline modified motor Unified Parkinson Disease Rating Scale (UPDRS).26 but not in Mini-Mental Status examination scores or change in UPDRS with levodopa (table 1). As a whole, PD patients demonstrated significant improvement in motor symptoms with levodopa at the time of the post-levodopa PET scans (modified UPDRS scale, mean percentage change = 35%).

All subjects provided written informed consent before participation in the study. The study protocol was approved by the Radioactive Drug Research Committee and the Human Studies Committee of Washington University School of Medicine. A subset of these scans have been previously compared with scans from PD patients with levodopa induced dyskinesias.13

**Protocol**

We performed PET scans on PD patients and controls at baseline and after an oral dose of levodopa. The specific methods are as follows:

**PET**

PET studies were performed in 2D mode on a Siemens 933B or 961 HR scanners (CTI, Knoxville, TN). Only 9 of the 44 subjects were scanned on the 961 scanner (five controls, two treated PD, and two levodopa naive PD subjects). On the 953B scanner, data were recorded simultaneously for 31 slices with a centre to centre slice separation of 3.4 mm. Axial and transaxial spatial resolution was about 4.5 mm full width at half maximum (FWHM) at slice centre in 2D mode.27 On the 961 scanner, data were recorded simultaneously for 47 slices with a 3.25 mm centre to centre slice separation. In plane transaxial and axial spatial resolutions were about 4 mm FWHM at slice centre in 2D wobbled mode. There are no gaps in data collection with either scanner. After subjects were positioned, a transmission scan used for individual attenuation correction was acquired with rotating rod sources containing 33Co/Ga.27 Images from both scanners were smoothed to the same in-plane pixel size of 2.086 mm.2 We then apply 3D smoothing (14 mm FWHM) to images from both scanners to obtain identical axial and transaxial resolutions. We then resample these 3D image sets after transformation into stereotactic coordinates in Talairach space. Finally, we normalise mean counts on a scan by scan basis to control for minor differences in the global counts achieved. These last steps make any small intrinsic differences in sampling, sensitivity, and resolution negligible. Blood flow was measured using a 40 second emission scan after the intravenous bolus injection of 5–10 ml of saline containing 40–50 mCi of 15O labelled water.28

PD subjects chronically treated with levodopa refrained from taking levodopa for at least 12 hours before the PET scans (“practical off”). On the morning before their scan, all subjects had a baseline clinical evaluation including UPDRS ratings, and then took 200 mg carbidopa orally. Subjects were placed in the scanner with an individually molded polyform mask to help minimise head movement. A 20 gauge catheter was inserted into an antecubital vein to permit injection of 15O. Some subjects also had a similar catheter inserted into the radial artery at the wrist after local lidocaine anaesthesia for arterial blood sampling.

Once these preparatory steps were completed, we performed two to three baseline 40 second PET measurements of blood flow 15 minutes apart.27 We then gave subjects levodopa/carbidopa (150 mg/37.5 mg) orally. About 45–75 minutes after levodopa/carbidopa administration, we collected two to three more 40 second PET measurements of blood flow 15 minutes apart. At the beginning of this study, we performed two baseline and two post-levodopa scans, and waited 75 minutes after levodopa before beginning to scan again. However, after obtaining levodopa plasma concentrations from the first set of subjects, we realised that plasma concentrations peaked between 30 and 45 minutes after levodopa administration and remained comparatively high for longer than anticipated. Thus, we revised our protocol to acquire three baseline and three post-levodopa PET scans, and only waited 45 minutes after administration before beginning to scan again. Importantly, levodopa levels at the time of the scan did not differ across groups and although subjects varied in the number of total scans performed (between four and six), we analysed a single contrast image (baseline compared with on levodopa scans) for each subject. In this manner, each subject contributed equally to our statistical analyses.

During each PET scan, the room was darkened and quiet, subjects’ eyes were closed, and subjects remained still. In between PET scans, we performed clinical ratings and obtained blood samples. The clinical ratings occurred after every scan, and consisted of a modified version of the motor subscale 3 from the UPDRS (ratings for tremor, rigidity, bradykinesia and tapping speed for upper extremities; 16 total possible points for each side, 32 points total). Blood samples were taken once before levodopa/carbidopa administration and then every 15 minutes after levodopa/carbidopa administration including samples done immediately after each subsequent PET scan. No clinical ratings or blood samples were performed during blood flow measurements. Each subject also had a high resolution anatomical MRI scan performed on the same day as the PET.

**Levodopa measurements**

Levodopa and carbidopa levels were measured using high performance liquid chromatography with electrochemical detection following a modified version of published methods.29 We added an internal standard, 3,4-dihydrobenzylamine (DHBA), to simplify quantification.

**PET analysis**

Data from both scanners were combined. Although the field of view was larger from the 961 PET scanner, we only analysed

---

**Table 1** Demographic and clinical variables

<table>
<thead>
<tr>
<th></th>
<th>Normals (n=16)</th>
<th>Levodopa naive (n=16)</th>
<th>Treated (n=12)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td>57.9 (13.7)</td>
<td>60.9 (12.3)</td>
<td>67.7 (6.4)</td>
<td>0.10</td>
</tr>
<tr>
<td><strong>Hamilton Depression</strong></td>
<td>1.0 (1.5)</td>
<td>2.4 (2.4)</td>
<td>1.3 (2.6)</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>Mini-Mental Score</strong></td>
<td>29.5 (9.9)</td>
<td>29.2 (0.7)</td>
<td>28.8 (1.2)</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>Baseline Modified UPDRS</strong></td>
<td>4.4 (1.2)</td>
<td>8.1 (5.4)</td>
<td>0.03</td>
<td></td>
</tr>
<tr>
<td><strong>Symptom duration</strong></td>
<td>3.0 (2.9)</td>
<td>7.2 (6.0)</td>
<td>0.02</td>
<td></td>
</tr>
<tr>
<td><strong>Treatment duration</strong></td>
<td>5.5 (5.4)</td>
<td>0.03</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td><strong>Modified UPDRS % change after acute dose of levodopa</strong></td>
<td>-39.9 (64.2)</td>
<td>-28.7 (50.1)</td>
<td>0.62</td>
<td></td>
</tr>
</tbody>
</table>

*Note total possible score on this modified UPDRS is only 32. Data shown as mean (SD).*
data from slices to which all subjects contributed. The brain coverage is best displayed in the sagittal view of figure 1. PET images first were aligned to individual subject MRIs and transformed to Talairach stereotactic space using previously described methods.\textsuperscript{38–37} This process was performed before images were imported into SPM. A person’s PET images were aligned to each other, then the averaged PET image for that person was warped to that person’s MRI scan using an 8 parameter transformation. Next, the MRI was warped to an averaged MRI already in Talairach atlas space (consisting of 12 normal adult brains) using a 12 parameter affine transformation. Using this transformation matrix, we then transformed the person’s PET directly into atlas space.\textsuperscript{39} Scans were normalised by setting mean qualitative blood flow for each scan to 1000. Spatial smoothing was done with a 14 mm gaussian filter. Effective resolution as determined by SPM was $x=14\text{ mm, } y=16\text{ mm, and } z=17\text{ mm}$. To statistically analyse the PET images, we used a random effects analysis implemented by the freely available SPM99 software package (http://www.fil.ion.ucl.ac.uk/spm/spm99. html). With this analysis, we examined the entire brain volume to determine where blood flow responses differed between groups, and where they were consistent across all subjects while providing adequate protection against type I error. Because of the rigour of this procedure, there may be increased type II error and modest effects may not be detected. However, this procedure strengthens the conclusions that can be drawn from group comparisons and has been recommended for groups of more than 12–16 members.\textsuperscript{30}

In random effects analyses, first a contrast image is made for each person to represent change in blood flow at each voxel from the baseline to the levodopa condition. Next, these contrast images were analysed with two sample $t$ tests to identify differences in the response to levodopa between two groups (between group comparison; treated PD compared with controls, levodopa naive PD compared with controls, treated PD compared with levodopa naive PD) or a one sample $t$ test to find significant areas of response to levodopa across all subjects. A $t$ value was assigned to each voxel in the brain. These $t$ maps were examined for voxels that exceeded a height threshold ($t=2.5$ for between group comparison or $t=3.0$ for the single group comparison). Clusters of these voxels that exceeded an extent threshold (set at 30) were identified. A multiple comparison correction for number of possible clusters of this size and magnitude in the brain volume was applied. Clusters that reached a corrected $p$ value of less than 0.05 then were considered for further analysis and interpretation.

The regions defined by these statistically determined clusters then were applied to the smoothed, normalised individual subjects’ images to obtain mean blood flow values within the clusters from the individual scans. Mean voxel values for the before and on levodopa conditions were calculated for each subject for each region. Comparisons were performed on these mean blood flow values using independent samples $t$ tests to determine the extent and direction of effects across conditions and groups. Pearson correlation coefficients were calculated between relevant clinical variables (UPDRS score, symptom duration, and treatment duration) and blood flow responses within groups for the significant clusters. Global blood flow values were analysed with a repeated measures general linear model, with group as the independent variable and condition (baseline, on levodopa) as the repeated measure.

**RESULTS**

**Between groups analysis**

SPM99 whole brain analyses revealed significant differences in the regional responses to a levodopa challenge between control and treated PD groups. SPM99 whole brain analyses did not reveal any significant differences between control and levodopa naive PD groups or between treated and levodopa

---

**Figure 1** “Glass brain” views of the comparison of levodopa induced responses in normal subjects compared with treated PD patients for $n=2.5$ threshold. No cluster threshold has been set to better illustrate the field of view of the data. The black arrow points to a coordinate within the left VLPFC.

**Figure 2** SPM99 display of voxel clusters that demonstrated significant effects (in colour) overlaid on a composite MRI (black and white) in atlas space. Voxels shown survived the height and cluster size threshold. However, not all clusters in the images survived the cluster level multiple comparison correction. (A) Coronal view of the left sensorimotor cortex region (SMC; indicated by arrow). Treated PD and controls responded significantly differently to levodopa in this region. The midline region that also appears in this image was not significant after correction for multiple comparisons. (B) Horizontal view of the left ventrolateral prefrontal cortex (VLPFC) region. Treated PD and controls responded significantly differently to levodopa in this region. (C) Sagittal view of the anterior cingulate and midbrain regions. A significant increase in blood flow after an acute dose of levodopa occurred in these regions, averaged across all subjects. (D) Coronal view of the right lateral inferior parietal region. A significant decrease in blood flow after an acute dose of levodopa occurred in this region, averaged across all subjects.
naive PD groups. The regions that were significantly different between control and treated PD groups were located in the left sensorimotor cortex (SMC) and left ventrolateral prefrontal cortex (VLPFC) (see table 2). The SMC region included both sides of the central sulcus along the superior-inferior extent (fig 2A). However, the most superior portion of the SMC was not sampled because of our limited field of view. The VLPFC region extended from Brodmann regions 44, 45, and 46 superiorly to areas 47 and the posterior portion of area 10 inferiorly (fig 2B). To characterise differences between groups and to determine the clinical relevance of these responses, we performed further analyses on the blood flow responses in these two regions.

SMC region

Figure 3A shows the differences in the SMC blood flow response to levodopa across the three groups. At baseline, the two PD groups were not significantly different from each other, but both were different from controls at a non-significant level (levodopa naive PD < controls, t=-1.8, p=0.08, treated PD < controls, t=-1.8, p=0.08). On levodopa, the groups did not differ significantly in mean blood flow for the SMC region. However, the change in blood flow in response to levodopa was different between the treated PD group and the controls (t=3.5, p=0.002). The treated PD group had decreased blood flow in this region whereas the control group had increased blood flow. Interestingly, the degree of change between baseline and levodopa conditions for the levodopa naive PD group (nearly zero) was intermediate between the treated PD group and the controls, but was significantly different from the controls only (dopa naive PD < treated PD, t=1.7, p=0.11; levodopa naive PD < controls, t=2.8, p=0.009). Within group analyses (one sample t tests) revealed that the control group had a significant increase in blood flow (t=3.2, p=0.006) and the treated PD group had a non-significant decrease in blood flow in the left SMC region (t=-1.9, p=0.08). The levodopa naive PD group did not have a significant response in the SMC (t=-0.3, p=0.72) (see fig 3A and 4A).

Age did not correlate significantly with response in this region, either within or across groups. Furthermore, we removed four of the youngest normal controls to provide a better age matched subsample for the treated PD group. This modification eliminated the age difference between the two groups (normal control mean age =64.3, SD=6.8; treated PD mean age =67.7, SD=6.4; t=−1.2, p=0.23), but did not change the difference in blood flow response to levodopa in the SMC (t=3.2, p=0.004).

Within the treated PD group, left SMC response correlated with baseline modified UPDRS (r=-0.72, p=0.008), such that patients with greater motor severity showed greater reduction of blood flow to levodopa in this region. This correlation was not significant in the levodopa naive patients (r=-0.06, p=0.83), but these patients were also less severely affected on average than the treated PD group. Covarying treatment duration (partial r=-0.76, p=0.007) or symptom duration (partial r=-0.73, p=0.001) did not change the significance of the relation in the treated group. No other clinical variables correlated significantly with the SMC response in this group. In addition, there was no difference in baseline blood flow or in the blood flow response in the SMC between patients with predominant left sided (n=4) compared with right sided (n=8) symptoms although it must be noted that our sample sizes were small (mean baseline blood flow in PET counts, right =1030 (SD=51.8), left=1086 (SD=66.6); mean change in blood flow with levodopa in PET counts, right=-3.3 % (SD=4.5), left=-3.3% (SD = 8.6); t tests, p values >0.14). Finally, average UPDRS baseline ratings from the left side compared with right side of the body correlated equally well with the blood flow response in the SMC within the treated PD group (right: r=-0.69, p=0.01; left: r=-0.68, p=0.02).

VLPFC region

Figure 2B shows the differences in the VLPFC blood flow response to levodopa across the three groups. At baseline, the treated PD group had higher regional blood flow than the levodopa naive PD group (t=2.1, p=0.049) and the controls (t=-3.0, p=0.007). On levodopa mean blood flow in this region did not differ between groups. However, blood flow in the treated PD group declined in this region whereas blood flow in the control group increased, and this difference was significant (t=5.2, p<0.001). Interestingly, the degree of change for the levodopa naive PD group was intermediate between the treated PD group and the controls, and was significantly different from both (levodopa naive PD < treated PD, t=3.1, p=0.005; levodopa naive PD < controls, t=2.4, p=0.025). Within group analyses (one sample t tests) revealed that the control group had a significant increase in blood flow (t=4.4, p<0.001) and the treated PD group had a significant decrease in blood flow in the left VLPFC region (t=-3.0, p=0.01). The levodopa naive PD group did not have a significant response in the left VLPFC (t=1.1, p=0.29) (see figs 3B and 4A).

Age did not correlate significantly with response in this region, either within or across groups. Furthermore, we removed four of the youngest normal controls to provide a
better age matched subsample for the treated PD group. This modification eliminated the age difference between the two groups, as described above, yet the difference in blood flow response to levodopa in the left VLPFC remained robust (t=4.90, p<0.001).

Within the treated PD group, left VLPFC response did not correlate with UPDRS scores or other clinical variables. In addition, there was no difference in baseline blood flow or in the blood flow response in the VLPFC between patients with predominant left sided (n=4) compared with right sided (n=8) symptoms although our sample sizes were small (mean (SEM) baseline blood flow in PET counts, right=1163 (18.2); mean (SEM) change in blood flow with levodopa in PET counts, right=1148 (15.2). In this smaller sample (midbrain: F(1,19)=13.2, p=0.002; VLPFC: F(1,19)=17.0, p=0.001) and (2) the significant main effect of drug on blood flow in the midbrain, anterior cingulate and right parietal regions found in the entire sample was still present in this smaller sample (midbrain: F(1,32)=71.2, p<0.001; anterior cingulate: F(1,32)=42.2, p<0.001; right parietal: F(1,32)=33.2, p<0.001).

To determine if group differences were also present in right SMC and right VLPFC blood flow

### Homologous right sided SMC and VLPFC blood flow

To determine if group differences were also present in right SMC and right VLPFC, we applied the left SMC and VLPFC regions to the right side of the brain (by flipping the regions defined in the SPM analysis from left to right) and obtained mean blood flow for each subject at baseline and on levodopa. We then calculated average change in blood flow induced by levodopa in these regions for each group. There were no significant changes in blood flow for any of the three groups (one tailed t tests, p values >0.27) (fig 4B). However, it should be noted that because of our restricted field of view, we cannot sample the most superior slices containing SMA.

### Levodopa responses across all subjects

Across all subjects, regional flow significantly increased in midbrain and anterior cingulate cortex yet significantly decreased in the right lateral inferior parietal cortex (table 2). The midbrain region was very large, extending from the upperpons to just below the thalami, covering the entire midbrain and bilateral subthalamic nuclei (fig 2C). The anterior cingulate and right lateral inferior parietal regions were comparatively restricted (fig 2C and 2D). There were no significant differences between groups in baseline, on levodopa blood flow or change in blood flow. All groups demonstrated a significant change in blood flow (one sample t tests, p values <0.05) (fig 5).

### Regional blood flow in 953b compared with 961 scans

Most of our scans were performed on the 953 scanner (35 of 44). Only five normal controls, two dopa naive PD, and two dopa treated PD were scanned on the 961 scanner. Because of the small sample sizes, it is impossible to perform meaningful statistical comparisons of blood flow responses between scanners. However, we did perform a repeated measures GLM on baseline and on levodopa blood flow in the SPM identified regions with only subjects who were scanned on the 953b scanner. These analyses demonstrated that (1) the significant group × condition interaction in the SMC and VLPFC regions found in the entire sample was still present in this smaller sample (SMC: F(1,19)=13.2, p=0.002; VLPFC: F(1,19)=17.0, p=0.001) and (2) the significant main effect of drug on blood flow in the midbrain, anterior cingulate and right parietal regions found in the entire sample was also present in this smaller sample (midbrain: F(1,32)=71.2, p<0.001; anterior cingulate: F(1,32)=42.2, p<0.001; right parietal: F(1,32)=33.2, p<0.001).

### Levodopa and carbidopa plasma concentrations

We were able to measure levodopa and carbidopa plasma concentrations in 38 of the 44 subjects. Levodopa concentrations peaked between 30 and 60 minutes after the oral dose of levodopa, and then remained above values found to provide symptomatic benefit in other studies for another 45 minutes (overall mean levodopa concentrations=1302 ng/ml, SD=598 ng/ml). During this time period, collection of the on levodopa blood flow measurements occurred. Carbidopa concentrations remained stable across the study (about 500–600 ng/ml). There were no significant differences among groups in levodopa concentrations at the time of the on levodopa scans and no significant correlations between levodopa concentrations and the regional changes in blood flow discussed above.

---

**Table 2 Regional effects of levodopa on blood flow; SPM99 cluster analysis results**

<table>
<thead>
<tr>
<th>Location of cluster</th>
<th>p value (corrected)</th>
<th>Direction of effect</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Differential effects of levodopa; treated PD v controls</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left VLPFC</td>
<td>0.049</td>
<td>−37 35 3 Increased blood flow</td>
</tr>
<tr>
<td>Left SMC</td>
<td>0.036</td>
<td>−39 23 47 Decreased blood flow</td>
</tr>
<tr>
<td><strong>Levodopa v baseline; all subjects</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midbrain</td>
<td>&lt;0.001</td>
<td>−9 −23 −25 Increase in blood flow</td>
</tr>
<tr>
<td>Anterior cingulate</td>
<td>&lt;0.001</td>
<td>−13 31 1 Increase in blood flow</td>
</tr>
<tr>
<td>Right inferior parietal</td>
<td>&lt;0.001</td>
<td>61 −39 11 Decrease in blood flow</td>
</tr>
</tbody>
</table>

---

**Figure 5** Means (SEM) for baseline and on levodopa blood flow in (A) midbrain, (B) anterior cingulate, and (C) right parietal for control group (circles), levodopa naive PD group (triangles), and treated PD group (squares). These three regions showed significant change in blood flow with levodopa over all subjects and within each group; there were no differences between groups at baseline, on levodopa or in the change in blood flow after levodopa administration.
Global blood flow

All regional data were analysed using normalised PET counts, which are linearly related within a given scan to quantitative regional cerebral blood flow. Absolute global blood flow was quantified in 21 subjects (five controls, nine levodopa naive PD patients, seven treated PD patients). Average baseline global blood flow was 59.0 ml/100 g/min (SD=14.6) and the average on levodopa absolute blood flow was 57.9 ml/100 g/min (SD=12.25). In a repeated measures general linear models analysis with group (controls, levodopa naive PD, treated PD) and condition (baseline, on levodopa) as factors, the main effects of group or condition were not significant, (group F(2,18)=2.7, p=0.10; condition F(1,18)=0.33, p=0.58) and neither was the interaction between the two (F(2,18)=0.001, p=0.99). Our finding that levodopa did not change global blood flow is consistent with other studies using adequate carbidopa pretreatment.

Discussion

This study showed that chronically treated PD patients have abnormal blood flow responses to an acute dose of levodopa in left sensorimotor cortex (SMC) and left ventrolateral prefrontal cortex (VLPFC) compared with controls. Chronically treated PD patients also responded differently from levodopa naive PD patients in these regions, but this difference was significant only in the VLPFC region. Within the treated PD group only, the SMC response was strongly associated with increased motor severity. In contrast, the VLPFC response in this group was not associated with motor severity.

The additional finding that motor symptoms correlate with the SMC response in treated but not levodopa naive PD suggests that both disease severity and chronic exposure to levodopa may be related to this abnormal blood flow response to levodopa. The availability of effective symptomatic treatment makes it difficult to separate disease severity from treatment exposure rigorously in PD patients as the more severely affected patients typically have been treated for a longer time. Interestingly, other data suggest that both long term treatment and increasing severity may contribute to the development of dyskinesias that represent an abnormal behavioural response to levodopa. We speculate that a similar pathogenic mechanism may be involved in PD patients because the severity and long term exposure to levodopa could interact to produce the functional abnormalities in specific dopaminergic pathways that we found in the absence of behavioural alterations. However, our study does not directly investigate this issue as none of the chronically treated PD patients in this study had levodopa induced dyskinesias.

Disease progression or chronic levodopa exposure could change the dopaminergic mediated input to SMC changing the SMC responses found in this study. The basal ganglia provide primary input to SMC and are a major site of action of dopamine. The net effect of dopamine activity in the striatum would be to reduce inhibition of internal pallidum on thalamic nuclei thereby increasing the activity of excitatory projections from thalamus to SMC. We postulate that the increased blood flow in SMC in controls in response to levodopa reflects the increased activity of these thalamocortical projections. The direct dopaminergic agonist apomorphine produced similar blood flow changes in SMC in another group of normal subjects. However, in chronically treated PD patients, baseline blood flow was non-significantly higher than controls, and with levodopa, blood flow decreased. Our data suggest that levodopa can decrease SMC input or local SMC activity in treated PD patients. Of course, levodopa induced changes in the pattern of neuronal firing may be more important than whether mean firing rates increase or decrease.

The dopaminergic system also has direct and indirect connections to the prefrontal cortex that could mediate the effects on VLPFC. The ventral tegmental area and the substantia nigra, pars compacta (SNpc) have direct dopaminergic connections to prefrontal cortex. Contact between these dopaminergic terminals and dendrites of upper pyramidal neurons of prefrontal cortex may allow them to modulate excitatory input. Furthermore, both basal ganglia output nuclei, substantia nigra pars reticulata (SNpr) and GPi project via specific thalamic nuclei to prefrontal cortex. GPI also sends direct inputs to lateral prefrontal cortex. Increased input from these pathways to the VLPFC or increased local VLPFC activity in response to levodopa may mediate the increased blood flow seen in controls. Long term treatment with levodopa could affect the response sensitivity of any of these pathways to levodopa causing a decrease in blood flow responses in the VLPFC after a dopaminergic challenge. Interestingly, the VLPFC has been implicated in a specific cognitive process, namely working memory, which is known to be deficient in PD and can be changed by dopaminergic agents.

This study also reports that levodopa activates midbrain and anterior cingulate regions to a similar degree in PD and controls. As these regions responded similarly across groups, these responses probably do not reflect PD pathophysiology. Previous animal and human studies support this finding and have demonstrated that dopamine agonists increase blood flow or metabolism in these regions in normal and dopamine deficient states. Although midbrain responses to levodopa or dopamine agonists are common in animal studies, to our knowledge our study is the first to report significantly increased blood flow in the midbrain in response to a dopaminergic challenge in humans with or without PD. Interestingly, the diffuse midbrain response seen here is similar to results obtained using 2-deoxyglucose ex vivo autoradiograms, which have a much higher resolution than our PET measures. We speculate that the midbrain response reflects a normal functional pathway including striatal-nigral input, pallidal input to superior colliculus and midbrain extraparamidal area and subthalamic nucleus inputs to SNpr. Levodopa's effect on blood flow in the anterior cingulate could reflect increased input from the ventral striatum or cortical-cortical connections. Finally, blood flow decreased in the right lateral inferior parietal region in response to levodopa across all subjects. Again, as this effect was similar across groups, it may not be relevant to PD pathophysiology. This general region has been affected by dopamine challenge in other studies. A dopamine agonist decreased baseline blood flow in parietal cortex in baboons. In addition, levodopa modulated parietal responses to a working memory task in Parkinson disease. Blood flow response to levodopa in the parietal region could reflect altered activity in the cortico-cortical connections, perhaps from prefrontal cortex.

The laterality of some of our findings (left SMC, left VLPFC) does not seem to be related to laterality of PD symptoms in a direct manner. However, we have seen a preferential left sided bias on effects of levodopa in the brain of other species and normal humans. Both awake and sedated normal animals (macaque and baboon) show asymmetric blood flow responses to levodopa in the putamen (left greater than right). In addition, we reported greater left than right putamen responses in normal humans after levodopa. To investigate the possibility that homologous right sided regions may have responded to levodopa but did not reach statistical significance, we examined the right SMC and right VLPFC regions in our blood flow data. We found no significant changes in either region on the right for any of the three subject groups (fig 4B). It should be noted, however, that we cannot sample the most superior slices of the brain containing SMC and so cannot draw conclusions about the entire superior-inferior extent of the SMC on either side of the brain. These results do indicate that frontal cortical regions can respond asymmetrically to a systemic levodopa challenge in both normal and PD groups. Thus, it seems highly unlikely that our lateralised results are a function of disease or disease...
severity. Although long term levodopa treatment can dramatically affect asymmetric motor responses to an acute dose of levodopa, no study has clearly examined neurophysiological and histopathological activities as a function of levodopa treatment history in PD patients.

In conclusion, we found that a dopaminergic challenge revealed normal and abnormal neural circuits in PD patients undergoing chronic levodopa treatment. We identified cortical asymmetries as a function of levodopa treatment history in PD patients.

ACKNOWLEDGEMENTS
We thank Tom O Videen, PhD, Lee Tempel, MD, and Ann-Mary MacLeod for expert assistance.

REFERENCES
38 Holmes AP, Friston KJ. Generalizability, random effects and population inference. Neuroimage 1998; 7: 57-64.


Long term treatment and disease severity change brain responses to levodopa in Parkinson’s disease

T Hershey, K J Black, J L Carl, L McGee-Minnich, A Z Snyder and J S Perlmutter

J Neurol Neurosurg Psychiatry 2003 74: 844-851
doi: 10.1136/jnnp.74.7.844

Updated information and services can be found at:
http://jnnp.bmj.com/content/74/7/844

These include:

References
This article cites 44 articles, 13 of which you can access for free at:
http://jnnp.bmj.com/content/74/7/844#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Drugs: CNS (not psychiatric) (1945)
- Parkinson's disease (690)
- Radiology (1747)
- Radiology (diagnostics) (1309)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/